ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Protective effects of gastrodin against bisphenol A-induced dopaminergic dysregulation and cognitive impairment in rats.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrodin (GAS) is a potent neuroprotective compound extracted from the traditional Chinese medicinal herb Gastrodia elata Blume. However, its role in mitigating bisphenol A (BPA)-induced dopaminergic dysfunction and cognitive impairment remains insufficiently explored. Many studies have shown that BPA exposure causes neurodegeneration via mechanisms involving dopaminergic system dysfunction, oxidative stress, and neuroinflammation. Therefore, the present study aimed to investigate whether GAS mitigates the effects of BPA-induced cognitive impairment through neuroinflammation in a rat model. Weanling male Wistar rats exposed to BPA (50 µg/kg b.wt. × 30 days, po) were subsequently treated with GAS at two dose levels (30 and 60 mg/kg b.wt., ip × 7 days). After 24 h, neurobehavioral functions (Barnes maze and Y-maze tests), cresyl violet staining, and ultrastructural analysis were performed, demonstrating significant memory deficits and neuronal degeneration in BPA-exposed rats. In contrast, GAS treatment significantly improved memory impairment and reduced neuronal cell death in the prefrontal cortex (PFC). mRNA, protein, and immunohistochemical expression of inflammatory markers such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), (Iba-1), glial fibrillary acidic protein (GFAP), and nuclear factor kappa B-p65 (NFκB-p65) were significantly increased in BPA-treated rats, indicating enhanced glial activation and neuroinflammation, whereas GAS effectively attenuated these alterations. Additionally, dopaminergic markers such as tyrosine hydroxylase (TH), dopamine transporter-1/solute carrier family 6 member 3 (DAT-1/SLC6A3), and dopamine receptor D4 (DRD4) were significantly downregulated following BPA exposure and were restored by GAS treatment. Overall, findings suggested that GAS exerts protection against BPA-induced neurotoxicity by suppressing NF-κB-mediated neuroinflammatory response and modulating dopaminergic signaling, thereby improving cognitive and neuronal outcomes in the PFC.
Indexed as
Identifiers
42185558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.